ASX:MSB Mesoblast (MSB) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free MSB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10.19 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.58%Price TargetN/A Stock AnalysisStock Analysis Get Mesoblast alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Mesoblast Stock (ASX:MSB)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. MSB Stock News HeadlinesApril 23, 2024 | fool.com.auIf you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!April 19, 2024 | americanbankingnews.comJane Bell Acquires 233,918 Shares of Mesoblast Limited (ASX:MSB) StockApril 25, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 5, 2024 | msn.comWhy the Mesoblast share price can rise another 60%March 28, 2024 | msn.comTop 5 Health Care Stocks That May Plunge In MarchMarch 27, 2024 | finance.yahoo.comAfter Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell TransplantMarch 26, 2024 | msn.comMesoblast gains as FDA backs regulatory plans for cell therapyMarch 15, 2024 | finance.yahoo.comMESO Mar 2024 3.000 putApril 25, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...March 11, 2024 | msn.comWhy is the Mesoblast share price jumping 16% on Monday?March 11, 2024 | markets.businessinsider.comMesoblast : FDA Backs Accelerated Approval For Rexlemestrocel-L In Heart Failure PatientsMarch 7, 2024 | msn.comAustralia stocks higher at close of trade; S&P/ASX 200 up 0.39%February 17, 2024 | finance.yahoo.comMESO Mar 2024 2.000 putFebruary 4, 2024 | afr.comWhat investors can learn from analysing R&D spendingJanuary 19, 2024 | afr.comMesoblast surges on FDA ‘rare paediatric disease’ designationJanuary 19, 2024 | msn.comIn Case You Missed It: A thing, a different thing and an amusing play on words, I guessJanuary 8, 2024 | finance.yahoo.comMesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years agoDecember 4, 2023 | fool.com.auWhy is the Mesoblast share price sinking 25% on Tuesday?November 27, 2023 | fool.com.auWhy are Mesoblast shares charging 5% higher today?November 21, 2023 | finance.yahoo.comMesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNovember 9, 2023 | morningstar.comMesabi Trust MSBNovember 8, 2023 | finance.yahoo.comWhile institutions own 25% of Mesoblast Limited (ASX:MSB), individual investors are its largest shareholders with 57% ownershipOctober 31, 2023 | fool.com.auMesoblast share price bleeds after chewing through $18.1 millionOctober 20, 2023 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 1.36%October 18, 2023 | finance.yahoo.comWhen Will Mesoblast Limited (ASX:MSB) Breakeven?September 26, 2023 | fool.com.auWhy is the Mesoblast share price beating the market today?September 21, 2023 | finance.yahoo.comKey Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalSee More Headlines Receive MSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:MSB CUSIPN/A CIKN/A Webwww.mesoblast.com Phone+61-3-96396036FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth9.56Net Income$-73,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-14.49% Return on Assets-5.61% Debt Debt-to-Equity Ratio23.98 Current Ratio2.71 Quick Ratio1.82 Sales & Book Value Annual Sales$7.47 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow30.00 Book ValueA$0.50 per share Price / BookN/AMiscellaneous Outstanding Shares1,010,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.48 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $1.13MDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $956.61kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJane BellBought 233,918 shares on 4/12/2024Total: $199,999.89 ($0.86/share)Philip FacchinaSold 290,432 sharesTotal: $82,773.12 ($0.29/share)Joseph SwedishBought 91,035 shares on 12/28/2023Total: $99,046.08 ($1.09/share)Philip FacchinaSold 30,000 sharesTotal: $32,400.00 ($1.08/share)Silviu ItescuSold 10,000,000 sharesTotal: $3 M ($0.30/share) MSB Stock Analysis - Frequently Asked Questions How were Mesoblast's earnings last quarter? Mesoblast Limited (ASX:MSB) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Genfit (GNFT), Pluristem Therapeutics (PSTI), Starpharma (SPL), Viking Therapeutics (VKTX), Alkane Resources (ALK) and Alcidion Group (ALC). This page (ASX:MSB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
